We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

BeiGene (NASDAQ:ONC) announced Tuesday that the U.S. Food and Drug Administration (FDA) approved its anti-tumor agent ...

Beigene, Ltd. (NASDAQ:ONC – Get Free Report)’s stock price gapped down prior to trading on Monday following insider selling activity. The stock had previously closed at $271.80, but opened at $255.83.

We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where ...

Bank of America upgraded shares of Beigene (NASDAQ:ONC – Free Report) from a neutral rating to a buy rating in a report published on Monday morning, MarketBeat.com reports. The brokerage currently has ...

BeiGene, Ltd. (ONC) shares ended the last trading session 3.2% higher at $244.20. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and ...

BeiGene (NasdaqGS:ONC) experienced a significant 29% price increase over the last quarter, supported by the FDA approval of TEVIMBRA for treating esophageal squamous cell carcinoma, a key development ...

If you’re interested in biotechnology stocks, billionaires Julian and Felix Baker are the ones to turn to.  According to ...

BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) ...